TVGN 489 POC Trial Experience has Validated the Utility and Compelling Potential of Tevogen’s Precision T Cell Technology and Cost-Efficient Cell Therapy Manufacturing Capability
- No dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome
- Correction of lymphopenia, reduction of inflammatory markers and viral load
- Trial patients were infected by Delta and a wide range of Omicron variants
We believe the perspective and expertise afforded by strategic collaborations to be fundamental in successful introduction of our lead product TVGN-489.
For collaboration inquiries please contact email@example.com
Corporate Executive Summary
Accessible Immunotherapies and Business Excellence Through Innovative Science
Purpose, Innovations, and Opportunity to Join Before Tevogen’s Next Growth Spurt
February 10th, 2023
Kindly fill out the form below to download the presentation.
Please contact us with collaboration inquiries at: